Rodrigues João Paulo Vilela, Pereira Lucas Borges, Zanetti Maria Olívia Barboza, Fontanella Andréia Turmina, Lima Nereida Kilza da Costa, Mengue Sotero Serrate, Pereira Leonardo Régis Leira
Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; +55 (16) 3315-0254.
Graduate Studies Program in Epidemiology, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul; +55 (51) 3308-5682.
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104912. doi: 10.1016/j.jstrokecerebrovasdis.2020.104912. Epub 2020 Jun 7.
Stroke accounts for approximately as 5.0% of disability-adjusted years of life and 10.0% of all deaths worldwide. Secondary stroke prevention in surviving individuals, which includes the use of statins, reduces atherothrombotic stroke recurrence, complications and mortality. The present study aimed to characterize the Brazilian population with stroke history and estimate the prevalence of statin use as secondary prevention.
This is a population-based cross-sectional study conducted in Brazilian urban areas. A total of 41.433 individuals were interviewed, representing 171 million of Brazilians, based on post-stratification weights. We included only participants aged 20 years or older who answered "yes" to the following question: "Did any doctor ever tell you that you had a stroke?" The main outcome was the prevalence of statin use among individuals who answered affirmatively. To identify the factors associated with stroke occurrence, the participants were categorized according to clinical and sociodemographic characteristics.
Only 24.2% (95% CI 19.9 - 29.1) of those who reported history of stroke regardless of other conditions also reported statin use. However, the results indicated that 52.9% (95% CI 43.6 - 62.0) of individuals who reported a previous diagnosis of dyslipidemia stated the use of statins. Regarding patients who reported stroke and did not report dyslipidemia history, only 9.1% (95% CI 5.9 - 13.8) referred to use statins.
This study showed a low prevalence of statin use by individuals with a history of stroke in Brazil. Actions involving the organization of services and training of professionals may positively impact the rates of stroke recurrence.
中风约占全球伤残调整生命年的5.0%，占全球所有死亡人数的10.0%。存活个体的二级中风预防，包括使用他汀类药物，可降低动脉粥样硬化血栓形成性中风的复发率、并发症和死亡率。本研究旨在描述有中风病史的巴西人群特征，并估计他汀类药物作为二级预防的使用 prevalence。
这是一项在巴西城市地区进行的基于人群的横断面研究。基于事后分层权重，共采访了41433人，代表1.71亿巴西人。我们仅纳入年龄在20岁及以上且对以下问题回答“是”的参与者：“是否有医生曾告诉你患有中风？”主要结局是对回答为肯定的个体中他汀类药物的使用 prevalence。为确定与中风发生相关的因素，根据临床和社会人口学特征对参与者进行分类。
在那些报告有中风病史而不考虑其他情况的人中，只有24.2%（95%置信区间19.9 - 29.1）也报告使用了他汀类药物。然而，结果表明，报告既往诊断为血脂异常的个体中有52.9%（95%置信区间43.6 - 62.0）表示使用了他汀类药物。对于报告有中风但未报告血脂异常病史的患者，只有9.1%（95%置信区间5.9 - 13.8）提及使用他汀类药物。
本研究表明，巴西有中风病史的个体中他汀类药物的使用率较低。涉及服务组织和专业人员培训的行动可能会对中风复发率产生积极影响。
